Agate Medical Investments

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.

CLEW Medical specializes in providing healthcare providers and administrators with high-accuracy predictive clinical analytics. Their innovative analytics engine detects deterioration in real-time and delivers predictive warnings during all phases of a patient’s ICU stay. Driven by innovative prediction models derived from Big Data analysis and an advanced high-dimensional analytics technique, CLEW's predictive platform has the flexibility to manage large patient populations without losing individualized treatment needs. CLEW's team represents decades of success in assisting healthcare institutions and other enterprises achieve their goals by exploiting breakthrough research and technologies.

their mission is to develop safe and effective neurovascular medical devices that are beneficial to patients and meet physicians' needs. They are committed to advancing patient care by providing the most reliable, easiest to use and highest quality products supported by proven clinical data. Rapid Medical is located at the northern part of Israel between the Carmel Mountain and the hills of Ramot Menashe.

CLEW Medical specializes in providing healthcare providers and administrators with high-accuracy predictive clinical analytics. Their innovative analytics engine detects deterioration in real-time and delivers predictive warnings during all phases of a patient’s ICU stay. Driven by innovative prediction models derived from Big Data analysis and an advanced high-dimensional analytics technique, CLEW's predictive platform has the flexibility to manage large patient populations without losing individualized treatment needs. CLEW's team represents decades of success in assisting healthcare institutions and other enterprises achieve their goals by exploiting breakthrough research and technologies.

Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery (MRCAS). The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view.

DiA Imaging Analysis provides advanced AI-based ultrasound analysis smarter and accessible. It solves the two main challenges clinicians face when using ultrasound: acquiring the right image and automatically analyzing it, to find clinical abnormalities that today they are struggling to find visually. DiA's automated tools can be easily be added to any ultrasound device or healthcare IT system, just like an App. The company holds FDA/CE Clearances for its cardiac toolbox, generating revenues and having thousands of users around the world.

Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.

Ornim Medical is an Israeli bio-medical high-technology company specializing in clinical research, development, and distribution of the highest quality medical devices for non-invasive patient monitoring specializing in the field of tissue and cerebral blood flow. Its two products, the CerOx™ and the c-FLOW™, are bedside patient monitors based on the patented UTLight™ technology designed to provide physicians with unique monitoring solutions that are imperative to individualized and personalized patient care. Both products enable precise, real time, continuous and non-invasive measurements of cerebral blood flow alerting physicians to variations in blood flow to the brain, thus enabling informed intervention for better clinical results and patient care. Ornim’s CerOx™ monitor is the only device in the market today enabling simultaneous, non-invasive measurement of both blood flow and oxygen saturation; while the c-FLOW™ is a pared down version used to measure the CBF only. The use of either of these products (depending on the clinical setting) is key to understand perfusion while helping to direct treatment and lower the cost of patient care. Ornim’s unique technology, protected by 13 worldwide granted and 15 worldwide pending patents, overcome limitations of Near Infrared Spectroscopy (NIRS) and ultrasound Doppler. The patented UTLight™ technology employs the combination of light and ultrasound to provide a non-invasive measure of regional blood oxygen saturation and blood flow. UTLight™ technology is unique among all other commercially available NIRS technologies, since it also analyzes the light speckle signal and does not rely solely on the intensity of light reaching the detector. Ornim Medical has developed a product range that was born out of a need – a need to measure blood flow directly. In other words, the products have the capabilities of direct measurement of flow (not surrogate like tissue oximetry); they are intuitive and comprehensive; actionable; the management of blood pressure (BP) according to CBF is intuitive; the measurement is robust and finally they are when adding the BP signal, the Autoregulation function of the organ can be assessed directly.

Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment. Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.

Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.